Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (1221)	1/28/2002 9:23:14 AM
From: Arthur Radley	Read Replies (1) \| Respond to of 1475

For those who refuse to get tetanus shots and venture over to Yahoo, the following is a post from a regular that knows his "stuff" about BTRN. "Wall Street Clueless on MEDI-507 by: soldier30 Long-Term Sentiment: Strong Buy 01/27/02 11:01 pm Msg: 1491 of 1494 In my opinion, analysts on the buy-side and the sell-side still have minimal appreciation of MEDI-507's potential: -many analysts peg this drug as having a $300 MM peak market potential-- --are they insane??--there are 7 million psoriasis patients in the US alone and according to a number of reports in the medical literature, 25-30% of this group has moderate-to-severe disease--at an annual cost of approximately $10,000-$12,000, only 25,000-30,000 patients would need to be treated yearly to generate 300MM in sales--hence, the Street is suggesting that the peak penetration of 507 is only 25,000 of the 1.75 MM patients with moderate-to-severe psoriasis???--this constitutes only 1/70th of the target population!!-- Obviously, I believe this number is way, way off-- Consider this: 1) it took Biogen over 10 months to enroll 1000 patients in their Phase 3 trial using 100 sites (trial started in early December, 1999 and enrollment, not dosing, was completed by mid-october 2000)--this comes out to 1 patient per site per month --MEDI-507 completed enrollment in its 420-patient trial over 102 days using 44 sites--this comes out to an average of 2.8 patients per site per month, nearly triple the enrollment rate Why? perhaps it's simply more effective recruiting by MEDI's investigators; perhaps they were incentivized better (more money, perhaps)--possible, but doubtful--my contacts at a number of trial sites have commented that word spread very quickly in the psoriasis community about MEDI-507's effects; there have been substantial numbers of patients who cleared or nearly cleared and many patients clamored to enroll.... 2) Amevive's last trials demonstrated only 21% PASI 75 with the IM formulation and 14% with the IV regimen; dose response-relationship was consistently lacking in past trials--a "middle-level" dose of Phase 2 trials was used for Phase 3 trials--MEDI-507 has thus far shown a 39% PASI 75 response at the highest doses utilized thus far and a consistent dose-response relationship was evident all the way to the highest doses tested--in fact, the maximum tolerated dose was not achieved in the Phase I/II trials and the dose continues to be pushed upward-- --hence, there is a good chance that MEDI-507's efficacy could be substantially better than Amevive--mechanistically, there is good reason to beleive this as well (not to mention the drug's potential in psoriatic arthritis, RA, T-cell malignancies, IBD and MS) To all of the non-believers in MEDI-507: if you are short, you are heading toward a major cataclysm beginning on February 20th ; if you are not yet in the stock, you may be missing a promising opportunity....